Teva has suspended its phase III study of a biosimilar of Rituxan, which it os jointly developing with Lonza. Lonza's shares fell as the company said the partners are evaluating how to move forward with testing as the regulatory environment for biosimilars gets more restrictive.
Fierce Biotech and Business Week
Sunday 7 October 2012
Lonza-Teva biosimilar on hold
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment